Sur­rozen paus­es PhI clin­i­cal tri­al in ul­cer­a­tive col­i­tis due to ad­verse events in liv­er

Just over a month af­ter Wnt play­er Sur­rozen hand­ed off its reti­nal dis­ease can­di­date to Boehringer In­gel­heim, the San Fran­cis­co biotech is re­port­ing clin­i­cal is­sues on its end.

Per a Q3 re­port re­leased Mon­day af­ter­noon, Sur­rozen has de­cid­ed to pause en­roll­ment in the as­cend­ing dose por­tion of a Phase I tri­al, which was test­ing can­di­date SZN-1326 in pa­tients with ul­cer­a­tive col­i­tis. As for why, the biotech said it ob­served “treat­ment-re­lat­ed ad­verse events,” with sev­er­al sub­jects ex­pe­ri­enc­ing “asymp­to­matic liv­er transam­i­nase el­e­va­tions,” in­clud­ing three sub­jects with grade 3 el­e­va­tions of as­par­tate transam­i­nase (AST) and ala­nine transam­i­nase (ALT).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER